Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in multiple myeloma

L C Moscinski1, O F Ballester

  • 1Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612.

Hematological Oncology
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IgM Myeloma: An IgM Gammopathy Distinct from Waldenstrom's Macroglobulinemia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.

Oncogene·2011
Same author

Cdc2: a monopotent or pluripotent CDK?

Cell proliferation·2011
Same author

Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.

Leukemia·2010
Same author

TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k).

Cell proliferation·2009
Same author

Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis.

Leukemia·2008
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Multiple myeloma is a cancer of mature plasma cells impacting bone marrow and causing disease. Understanding early cell differentiation and utilizing advanced techniques can improve prognosis and guide treatment strategies for patients.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Multiple myeloma is a plasma cell neoplasm causing bone marrow infiltration and cytokine-mediated bone disease.
  • It involves a complex cellular network sustaining myeloma proliferation and immunoglobulin secretion.
  • While mature plasma cells are the hallmark, early lymphoid cells also play a role in the proliferative pre-plasma cell compartment.

Purpose of the Study:

  • To enhance understanding of multiple myeloma cell biology and early pre-plasma cell differentiation.
  • To explore how advanced techniques can yield new prognostic information for multiple myeloma patients.
  • To improve the identification of patients requiring innovative or aggressive treatment protocols.

Main Methods:

  • Utilizing high-resolution flow cytometry.

Related Experiment Videos

  • Employing flow cytometric DNA analysis.
  • Improving karyotypic data acquisition in multiple myeloma.

    • Main Results:

    • Studies on normal non-neoplastic equivalents aid understanding of early pre-plasma cell differentiation.
    • Advanced techniques are expected to improve insights into myeloma cell biology.
    • Improved prognostic assessment will aid in patient stratification for treatment.

    Conclusions:

    • Further research into myeloma cell biology and differentiation is crucial.
    • Advanced techniques like flow cytometry and karyotyping offer promise for improved prognosis.
    • Accurate prognosis is essential for tailoring treatment strategies and identifying patients for aggressive protocols.